The short version of hGH fragment fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-08-21. Anything still debated is marked as such rather than presented as settled.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Peptide fragment | Corresponds to hGH residues 176-191 |
| Common synonyms | AOD9604, hGH 176-191 | Also written as AOD-9604 |
| Typical form | Lyophilized powder | Often supplied in sealed vials |
| Solubility | Water-soluble | Dissolves in aqueous buffers |
| Regulatory status | Not approved as drug | Banned in sport; varies by country |
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
== Importance == Many urine tests (urinalysis) monitor the amount of urobilin in urine, as its levels can give insight on the effectiveness of urinary tract function. Normally, urine would appear as either light yellow or colorless. A lack of water intake, for example following sleep or dehydration, reduces the water content of urine, thereby concentrating urobilin and producing a darker color of urine. Obstructive jaundice reduces biliary bilirubin excretion, which is then excreted directly from the blood stream into the urine, giving a dark-colored urine but with a paradoxically low urobilin concentration, no urobilinogen, and usually with correspondingly pale faeces. Darker urine can also be due to other chemicals, such as various ingested dietary components or drugs, porphyrins in patients with porphyria, and homogentisate in patients with alkaptonuria.
== Treatment == For newborn infants starved of oxygen during birth, there is now evidence that hypothermia therapy for neonatal encephalopathy applied within 6 hours of cerebral hypoxia effectively improves survival and neurological outcome. In adults, however, the evidence is less convincing and the first goal of treatment is to restore oxygen to the brain. The method of restoration depends on the cause of the hypoxia. For mild-to-moderate cases of hypoxia, removal of the cause of hypoxia may be sufficient. Inhaled oxygen may also be provided. In severe cases, treatment may also involve life support and damage control measures. A deep coma will interfere with the body's breathing reflexes even after the initial cause of hypoxia has been dealt with; mechanical ventilation may be required. Additionally, severe cerebral hypoxia causes an elevated heart rate, and in extreme cases the heart may tire and stop pumping. CPR, defibrilation, epinephrine, and atropine may all be tried in an effort to get the heart to resume pumping. Severe cerebral hypoxia can also cause seizures, which put the patient at risk of self-injury, and various anti-convulsant drugs may need to be administered before treatment.
=== Domestic pressures in the US === Some critics have described the United States intervention against Iran as a diversionary war, noting mounting domestic pressures including intense public scrutiny following the publication of the Epstein files, Operation Metro Surge by ICE, and the economic impact of global tariffs which have contributed to falling approval ratings and legal actions. Representative Thomas Massie and former Representative Marjorie Taylor Greene argued Trump started the war as a distraction from the Epstein files.
=== Praja Shakti Democratic Party === On 21 August 2022, Vaghela launched a new party, Praja Shakti Democratic Party, with an intention to contest 2022 Gujarat Legislative Assembly election. Later he backed the INC instead.
==== Omega-6:omega-3 ratio ==== A 2024 review stated that dietary recommendations should not be made based on the omega-6:omega-3 ratio, but rather on their absolute dietary intake levels. The omega-6:omega-3 ratio is calculated by accounting for all of the omega-6 fatty acids in the diet or blood divided by the sum of all omega-3 fatty acids. Concern about a high omega-6:omega-3 ratio was based on the competition between linoleic acid and alpha-linolenic acid for desaturation enzymes, and because metabolites of omega-6 fatty acids were considered to be pro-inflammatory. However, there is insufficient evidence in humans that omega-6 fats are pro-inflammatory and that omega-3 fats are anti-inflammatory. In contrast, higher omega-6 levels are associated with lower inflammatory status, indicating that intake of omega-6 fats is not a dietary concern, and that relatively low intake of dietary omega-3 fats may lead to inflammation. Accordingly, use of the omega-6:omega-3 ratio has been rejected as an inflammation biomarker by health agencies worldwide. Numerous health and scientific organizations recommend intake of omega-6 seed oils as part of a healthy diet to replace sources of saturated fats, such as in palm and coconut oils, butter, tallow, and lard.
Sources: en.wikipedia.org
The word "aptamer" is a neologism coined by Andrew D. Ellington and Jack Szostak in their first publication on the topic. They did not provide a precise definition, stating "We have termed these individual RNA sequences 'aptamers', from the Latin aptus, to fit." The word itself, however, derives from the Greek word ἅπτω, to connect or fit (as used by Homer (c. 8th century BC)) and μέρος, a component of something larger. A typical aptamer is a synthetically generated ligand exploiting the combinatorial diversity of DNA, RNA, XNA, or peptide to achieve strong, specific binding for a particular target molecule or family of target molecules. Aptamers are occasionally classified as "chemical antibodies" or "antibody mimics". However, most aptamers are small, with a molecular weight of 6-30 kDa, in contrast to the 150 kDa size of antibodies, and contain one binding site rather than the two matching antigen binding regions of a typical antibody.
On August 12, 2011, Valve announced the production of a successor to Counter-Strike: Source, entitled Counter-Strike: Global Offensive. Global Offensive's development began in March 2010 when Hidden Path Entertainment attempted to port Counter-Strike: Source onto video game consoles prior to the end of its lifespan. During its development, Valve saw the opportunity to turn the port into a full game and expand on the predecessor's gameplay. In 2023, Global Offensive was assimilated into Counter-Strike 2, which ported the game's content into the Source 2 engine.
==== United States ==== The price of insulin in the United States dramatically increased from 1991 to 2019, prompting state governments to sue pharmaceutical companies over alleged price fixing. In 2019, the House Committee on Energy and Commerce questioned how the annual cost of insulin for treating Type 1 diabetes rose to $5,705 by 2019 ($7,184 in 2025), which was up to six times higher than prices in other countries. In 2020, President Donald Trump established the Part D Senior Savings Model for some Medicare Part D plans to offer insulin at $35 or less per month. In 2022, President Joe Biden signed the Inflation Reduction Act, requiring all Part D plans to adopt this price ceiling and cost sharing under Medicare Part B to follow the same threshold. In 2022, California allocated $100 million for the state to create its own insulin at a close-to-cost price.
== Composition == Silk is made up of two primary proteins; a fibrous protein known as fibroin, and a sticky protein known as sericin, with the two comprising 70–80% and 20–30% of silk, respectively. The source of these silk amino acids is typically the cocoons of the domestic silk moth, Bombyx mori, although other sources are known. Silk peptides are produced by acid hydrolysis of silk followed by neutralization of excess acid, filtration, and further processing steps to remove salts and other impurities followed by freeze drying. The resultant product contains a mixture of peptides typically between 2 and 20 amino acids in length, with a major component being the 18 amino acid fragment GAGAGSGAGAGSGAGAGS comprising three repeat units of the β‑sheet motif Gly-Ala-Gly-Ala-Gly-Ser derived from the repetitive crystalline domain of silk fibroin protein.
Naturally, the Petrich district—which the Macedonian revolutionaries had previously controlled—was one of them. With Yugoslavia a trade treaty was made and at the end of September, Alexander I made a visit to Sofia in which he was welcomed by thousands of people. Kimon intensified negotiations with the Soviet Union initiated by the previous cabinet and in July 1934, the first diplomatic relations were made between the two countries. In the autumn of 1934, a pro-monarchist wing led by Pencho Zlatev and a pro-republican wing led by Damyan Velchev took shape in the ruling circles of the Zveno and Military Union. Kimon Georgiev began measures to remove Zlatev from his War Office, but its unsuccessful, due to the leadership of the Military Union resisting. Damyan Velchev remained in isolation after the Union's Congress in November with the organization rejecting much of the cabinet's policies. On 22 January 1935, Boris III executed a counter-coup to strength his role in Bulgarian politics, in which Georgiev resigned and Pencho Zlatev took control as a pro-monarchist. Kimon Georgiev was given a chance to be Minister of Justice, but declined.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.
No, it is a small fragment of the full growth hormone protein. It does not appear to stimulate growth or increase growth hormone levels in the same way. Its actions are thought to be more limited to metabolic pathways.
Regulatory status varies. It is not approved for medical use in the United States or many other countries. It is banned in sport by WADA, and its sale as a supplement or research chemical may be subject to legal restrictions.
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.